Onderzoek naar de noodzaak van correctie van bloedplaatjestekort voor het plaatsen van een centraal veneuze lij
Completed
- Conditions
- Central venous catheter, CVC, centraal veneuze lijn, coagulopathy, coagulopathie, platelet count, thrombocytopenia, trombocytopenie
- Registration Number
- NL-OMON27018
- Lead Sponsor
- Acamedic Medical Center
- Brief Summary
one
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 392
Inclusion Criteria
1.Age>18 years
2.Need for CVC placement at the clinician’s discretion
Exclusion Criteria
1.Use of therapeutic anticoagulant therapy, except single antiplatelet therapy
2.Contra-indication for PC transfusion, such as Thrombotic thrombocytopenic purpura, or Congenital IgA deficiency
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A procedure-related relevant bleeding, occurring within 24 hours after the procedure. A WHO grade 2-4 (appendix I) up to 24 hours of randomization is defined as relevant bleeding. Secondary study parameters/endpoints (if applicable)
- Secondary Outcome Measures
Name Time Method - WHO grade 1 bleeding within 24 hours of CVC placement (appendix I)<br /><br>- Adjusted WHO bleeding score, HEME-bleeding score (appendices II and III)<br /><br>- Allergic transfusion reaction within 24 hours<br /><br>- Onset of acute lung injury within 48 hours.<br /><br>- Length of hospital stay<br /><br>- Number of RBCs and PC transfusions within 24 hours<br /><br>- Costs<br /><br /><br><br>Hemoglobin and platelet count will be measured prior to the procedure and one hour and at 24 hours after the procedure and when clinically indicated. This is according to standard care. <br>